0.08
0.00%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Inhibitor Therapeutics
From its filings with the US Securities and Exchange Commission
Inhibitor Therapeutics is based in Tampa, Florida and is incorporated in Delaware. Its shares trade on OTC under the ticker INTI. The SEC classifies its business as pharmaceutical preparations. In the fiscal year to 31 December 2021, it reported revenue of $0.
BCCNS. The FDA has since informed us that the request has been granted as a Type C meeting, with written responses expected in May 2026.
HP2001 efficacy and safety dataset, and the potential use of expedited programs and a 505(b)(2) new drug application pathway.
VE, et al. Clinical manifestations in 105 persons with nevoid basal cell carcinoma syndrome.
2015). As a result, many patients with BCCNS continue to rely primarily on repeated procedural interventions over time.
Academy of Dermatology (AAD). Guidelines of Care for the Management of Basal Cell Carcinoma.
A, et al. Efficacy and safety of vismodegib in advanced basal-cell carcinoma. N Engl J Med.
February 2026 FDA meeting materials, the study enrolled 38 patients with 477 surgically eligible target basal cell carcinomas at baseline.
In those materials, we reported a per-lesion objective response rate of 57.7% and a patient-level disease control rate of 97.4%.
CR, et al. Inhibition of angiogenesis by the antifungal drug itraconazole. Cancer Cell. 2007;11:403–413.
BT, et al. Itraconazole inhibits angiogenesis and tumor growth. Cancer Res. 2011;71:6764–6772.
Quoted from its 10-K, filed 26 Mar 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 5 Mar 1996
- Employees
- 2
- Website
- hedgepathpharma.com ↗
- Head office
- 4830 W. KENNEDY BLVD., TAMPA, FL, 33609
- Incorporated in
- DE
- Classification
- Pharmaceutical Preparations
- Filer status
- Non-accelerated filer<br>Smaller reporting company
Leadership
Pay as last reported
- Dr. Francis O'DonnellExecutive Chairman of the Board, Chief Executive Officer, since 2022$1.1m
- Mr. James McnultyInterim Chief Financial Officer, Treasurer, Secretary$359,756
- Mr. Ronald OsmanDirector$23,500
- Mr. Michael JermanIndependent Director$23,500
- Mr. Samuel SearsIndependent Director$23,500
- Dr. Niraj VasishtIndependent Director$23,500
- Ms. Michelle YanezIndependent Director$23,500
- Mr. Simon BettinkVice President of Operations, since 2024
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Inhibitor Therapeutics Inc has a strong research and development team that is dedicated to discovering and developing innovative therapeutics. This allows the company to constantly innovate and stay ahead in the highly competitive pharmaceutical industry.
- The company holds a significant number of patents for its drug candidates, providing a competitive advantage and protection against potential infringements by other companies. This enables Inhibitor Therapeutics Inc to generate revenue from licensing agreements and maintain a strong market position.
Weaknesses
- Inhibitor Therapeutics Inc currently has limited market presence and brand recognition compared to its larger competitors. This can make it challenging for the company to attract investors and gain market share in a highly regulated industry.
- The company heavily relies on external funding sources, such as grants and partnerships, to support its research and development efforts. This dependency can expose Inhibitor Therapeutics Inc to uncertainties and fluctuations in funding availability, which may impact its ability to execute its strategic plans.
Opportunities
- The growing demand for pharmaceutical products in emerging markets presents an opportunity for Inhibitor Therapeutics Inc to expand its market reach. By strategically entering these markets, the company can tap into new customer segments and potentially increase its sales and revenues.
- Advancements in technology, such as genomics and personalized medicine, offer opportunities for Inhibitor Therapeutics Inc to develop targeted therapies and enhance treatment outcomes. By leveraging these advancements, the company can differentiate itself from competitors and gain a competitive edge in the market.
Threats
- Inhibitor Therapeutics Inc operates in a highly regulated industry, which exposes the company to potential regulatory challenges. Changes in regulations or delays in obtaining necessary approvals can significantly impact the development and commercialization of its products, leading to potential revenue loss.
- The pharmaceutical industry is highly competitive, with numerous well-established players. Inhibitor Therapeutics Inc faces strong competition from both large pharmaceutical companies and smaller biotechnology firms, which can pose challenges in terms of market share, pricing pressures, and attracting top talent.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.